相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation
Dominik Feuerbach et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition: A Proof of Concept, Randomized Trial in Patients with Schizophrenia
Sheldon H. Preskorn et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2014)
AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys
Therese Di Paolo et al.
PARKINSONISM & RELATED DISORDERS (2014)
Preclinical characterization of a selective alpha-7 neuronal nicotinic acetylcholine receptor agonist ABT-126: A novel therapeutic agent for the treatment of cognitive impairment in Alzheimer's disease and schizophrenia
Robert Bitner et al.
Alzheimers & Dementia (2013)
3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats
Syuuichirou Suzuki et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2013)
Which dyskinesia scale best detects treatment response?
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2013)
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia
Jeffrey A. Lieberman et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Nicotinic Receptor Agonists Reduce L-DOPA-Induced Dyskinesias in a Monkey Model of Parkinson's Disease
Danhui Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Discovery of (2S,3R)-N-[2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a Selective α7 Nicotinic Acetylcholine Receptor Agonist, for the Treatment of Cognitive Disorders
Anatoly A. Mazurov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
Irene Litvan et al.
MOVEMENT DISORDERS (2012)
EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors
Jos Prickaerts et al.
NEUROPHARMACOLOGY (2012)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
Klaus Seppi et al.
MOVEMENT DISORDERS (2011)
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats
Luping Z. Huang et al.
NEUROPHARMACOLOGY (2011)
TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia
T. A. Hauser et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys
Luping Z. Huang et al.
JOURNAL OF NEUROCHEMISTRY (2009)
The selective nicotinic acetylcholine receptor alpha 7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain
Dominik Feuerbach et al.
NEUROPHARMACOLOGY (2009)
Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease
Tanuja Bordia et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Maryka Quik et al.
ANNALS OF NEUROLOGY (2007)
Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
JN403, in vitro characterization of a novel nicotinic acetylcholine receptor α7 selective agonist
Dominik Feuerbach et al.
NEUROSCIENCE LETTERS (2007)
Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals
Marina G. Falleti et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY (2006)
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates
Maryka Quik et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle
N. P. Visanji et al.
NEUROPHARMACOLOGY (2006)
Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia
Ann Olincy et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates
M Quik et al.
JOURNAL OF NEUROSCIENCE (2006)
The selective α7 nicotinic acetylcholine receptor agonist PNU-282987[N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats
M Hajós et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Impact of the motor complications of Parkinson's disease on the quality of life
S Chapuis et al.
MOVEMENT DISORDERS (2005)
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers
H Kitagawa et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice
RE Ryan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice
K Parain et al.
BRAIN RESEARCH (2001)
分享论文
